持効型インスリン注射併用薬をDPP-4 阻害薬からGLP-1 受容体作動薬へ切り替え著効を得た糖尿病血液透析患者の1 例

機関リポジトリ Web Site

書誌事項

タイトル別名
  • Switching from a DPP-4 Inhibitor to GLP-1 Receptor Agonist Was Effective in a Diabetic Patient Treated with Long-Acting Insulin Injections and Undergoing Hemodialysis: A Case Report
  • 症例報告 持効型インスリン注射併用薬をDPP-4阻害薬からGLP-1受容体作動薬へ切り替え著効を得た糖尿病血液透析患者の1例
  • ショウレイ ホウコク ジコウガタ インスリン チュウシャ ヘイヨウヤク オ DPP-4 ソガイヤク カラ GLP-1 ジュヨウタイ サドウヤク エ キリカエ チョコウ オ エタ トウニョウビョウ ケツエキ トウセキ カンジャ ノ 1レイ

この論文をさがす

説明

A diabetic female patient in her 80s being treated with sustained insulin and a dipeptidyl peptidase-4（DPP-4）inhibitor was undergoing hemodialysis. However, her level of glycated albumin（GA）, an indicator of glycemic control in diabetic patients undergoing hemodialysis, was greater than 25%; therefore, insulin was increased. Since GA did not decrease even with the increase in insulin, her diabetes medication was switched from a DPP-4 inhibitor to glucagon-like peptide-1（GLP-1）receptor agonist without a change in the units of insulin. GA subsequently decreased, and blood glucose（BG）control improved with no hypoglycemia. When the effects of medication are insufficient, a change to that with different actions may be effective. Therefore, a switch to medication with different actions needs to be considered in order to obtain better therapeutic effects.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ